Qube Research & Technologies (QRT)
BMRN icon

Qube Research & Technologies (QRT)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.3M Sell
668,835
-20,886
-3% -$1.14M 0.04% 594
2026
Q1 		$39M Sell
689,721
-746,918
-52% -$43.5M 0.04% 533
2025
Q4 		$85.4M Buy
1,436,639
+1,176,410
+452% +$64M 0.09% 299
2025
Q3 		$14.1M Sell
260,229
-380,164
-59% -$21.7M 0.01% 1102
2025
Q2 		$35.2M Buy
+640,393
New +$37.7M 0.04% 600
2025
Q1 		– Sell
-6,576
Closed -$432K – 3499
2024
Q4 		$432K Buy
+6,576
New +$440K ﹤0.01% 2544
2024
Q3 		– Sell
-14
Closed -$1.15K – 3345
2024
Q2 		$1.15K Sell
14
-14,835
-100% -$1.24M ﹤0.01% 3246
2024
Q1 		$1.3M Buy
14,849
+4,319
+41% +$387K ﹤0.01% 1992
2023
Q4 		$1.02M Sell
10,530
-71,145
-87% -$6.29M ﹤0.01% 1921
2023
Q3 		$7.23M Sell
81,675
-407,530
-83% -$36.3M 0.02% 771
2023
Q2 		$42.4M Buy
489,205
+12,454
+3% +$1.17M 0.15% 186
2023
Q1 		$46.4M Buy
476,751
+211,481
+80% +$21.9M 0.2% 98
2022
Q4 		$27.5M Buy
265,270
+169,933
+178% +$16M 0.15% 185
2022
Q3 		$8.08M Buy
+95,337
New +$8.49M 0.05% 467
2022
Q2 		– Sell
-268,780
Closed -$20.7M – 2520
2022
Q1 		$20.7M Buy
+268,780
New +$22.5M 0.18% 146
2021
Q4 		– Sell
-24,205
Closed -$1.87M – 2537
2021
Q3 		$1.87M Buy
24,205
+10,252
+73% +$809K 0.02% 699
2021
Q2 		$1.16M Buy
13,953
+3,197
+30% +$253K 0.01% 880
2021
Q1 		$812K Buy
+10,756
New +$879K 0.01% 934
2020
Q4 		– Sell
-52,118
Closed -$3.96M – 1821
2020
Q3 		$3.96M Buy
52,118
+45,906
+739% +$4.64M 0.06% 433
2020
Q2 		$766K Buy
+6,212
New +$617K 0.01% 956
2019
Q3 		– Sell
-6,387
Closed -$547K – 262
2019
Q2 		$547K Buy
6,387
+2,334
+58% +$200K 0.13% 169
2019
Q1 		$360K Buy
+4,053
New +$376K 0.05% 366
2018
Q4 		– Sell
-2,704
Closed -$262K – 364
2018
Q3 		$262K Buy
+2,704
New +$270K 0.03% 395

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Qube Research & Technologies (QRT)'s BMRN Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its BioMarin Pharmaceuticals (BMRN) stake by 3% in Q2 2026, selling an estimated $1.14M and leaving 668,835 shares worth $38.3M. The position accounts for 0.04% of the portfolio, ranked #594.

Qube Research & Technologies (QRT) first reported a position in BMRN in Q3 2018 and has held it in 23 quarters since. The position peaked at $85.4M in Q4 2025. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Qube Research & Technologies (QRT) held 668,835 shares of BioMarin Pharmaceuticals worth $38.3M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 20,886 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.14M.
  • BioMarin Pharmaceuticals made up 0.04% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #594 holding.
  • Qube Research & Technologies (QRT) first reported a position in BioMarin Pharmaceuticals in Q3 2018 and has held it in 23 quarters since.
  • Qube Research & Technologies (QRT)'s BioMarin Pharmaceuticals position peaked at $85.4M in Q4 2025.
  • 565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.